Francis Crick Institute
UK Consortium Launches With Public-Private Funding to ID Immunotherapy Biomarkers
The Francis Crick Institute and the Royal Marsden Foundation Trust are spearheading the MANIFEST project with £21.9 million in government and industry funding.
In New TRACERx Data, Personalis MRD Test Shows Improved Sensitivity With Potential Clinical Impact
Premium
The data, some of the first available for the firm's NeXT Personal test, indicated that its higher analytical sensitivity could lead to better risk prediction than competing tests.
New Lung Cancer Evolution, Treatment Response Patterns Emerge From TRACERx Study
TRACERx researchers reported on non-small cell lung cancer features linked to disease progression, recurrence, treatment response, and more in seven new papers.
Personalis MRD Assays to Support UK's TRACERx ctDNA Monitoring Study
The ongoing lung cancer study, which has employed other assays in the past, will now use the Personalis NeXT Personal platform to monitor for recurrence after surgery.
Cancer Genome Analysis Points to Biallelic Mutations to Inform Variant Interpretation
Investigators saw mutations affecting both maternal and paternal alleles in 21 percent of tumors in a pan-cancer collection, including mutations reflecting a tumor's mutagenic history.